RxDoctor Payments Data

David Hayes, MD

Family Medicine · Evansville, INNPI 1295725943

Payments from drug & device makers

$6,625in general payments, 2019–2025

Across 461 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$862
  • Amgen$777
  • Novo Nordisk$725
  • AbbVie$502
  • Johnson & Johnson$346
  • Lilly USA, LLC$320
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$6,522100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,625 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$147,920
Medicare patients
333
Services billed
5,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban477$222,645
OzempicSemaglutide167$219,814
TrulicityDulaglutide101$111,746
XareltoRivaroxaban145$81,501
GemtesaVibegron232$67,326
JardianceEmpagliflozin76$46,422
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$42,735
EntrestoSacubitril/Valsartan114$40,600
TradjentaLinagliptin115$38,001
MyrbetriqMirabegron89$37,333
LinzessLinaclotide50$36,615
NuedextaDextromethorphan Hbr/Quinidine42$32,657
JanuviaSitagliptin Phosphate22$31,810
MounjaroTirzepatide20$27,134
XifaxanRifaximin17$25,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$264$236,087520 claims
Novo NordiskOzempic, Fiasp$725$228,842196 claims
Lilly USA, LLCTrulicity, Mounjaro$320$138,880121 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$71$91,983206 claims
Johnson & JohnsonXarelto$346$81,501145 claims
Sumitomo Pharma America, Inc.Gemtesa$42$67,326232 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$862$63,343111 claims
AbbVieLinzess, Vraylar$502$54,75861 claims
NovartisEntresto$171$40,600114 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor$108$40,06631 claims
Astellas Pharma US IncMyrbetriq$132$37,33389 claims
Avanir Pharmaceuticals, Inc.Nuedexta$91$32,65742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →